More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease

Dig Liver Dis. 2023 Feb;55(2):298-299. doi: 10.1016/j.dld.2022.11.004. Epub 2022 Nov 19.

Authors

Toshihiko Kakiuchi¹, Masato Yoshiura²

Affiliations

¹ Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan. Electronic address: kakiucht@cc.saga-u.ac.jp.
² Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.

PMID: 36411192
DOI: 10.1016/j.dld.2022.11.004

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Biological Therapy
Gastrointestinal Agents / therapeutic use
Humans
Inflammatory Bowel Diseases* / drug therapy

Substances

vedolizumab
Antibodies, Monoclonal, Humanized
Gastrointestinal Agents